glp 1 agonists tirzepatide GLP-1 Medications for Weight Loss: Semaglutide vs vs Retat – Revolution Health & Wellness GLP-1 Receptor Agonist Shortage: Challenges

A positive outcome of adding Wegovy to formularies is the reduction of inappropriate use of Ozempic for indications other than diabetes

They also slow gastric emptying (producing feelings of fullness) and trigger feelings of satiation in the brain

Importantly we still do not know the impact they will have on patients who take them long-term

In REDEFINE 2, which included participants with type 2 diabetes (a population that typically shows lower weight loss with any intervention), CagriSema achieved 13.7% weight loss compared to 3.4% with placebo

Baggio LL, Huang Q, Brown TJ, Drucker DJ, Baggio LL, Huang Q, et al

Europe represents a large market for oral GLP-1 agonists because it has well-developed healthcare and chronic disease management systems that aim at optimizing healthcare outcomes